May 22, 2020 | 4:12 pm

Researchers from the Beijing Biotechnology Institute, CanSino Biologics and specialists from six other institutes revealed that the results of the first phase of a COVID-19 vaccine developed in China are promising.

The vaccine was found to generate antibodies and T lymphocytes, according to the article published in The Lancet.

The dose was applied to 108 healthy volunteers, divided into three groups, who were given a vector vaccine with recombinant adenovirus type 5 (Ad5) that expresses the spike glycoprotein of a SARS-CoV-2 strain.

“Like traditional vaccines, recombinants teach the body to effectively fight certain infections. These types of doses are created à la carte in the laboratory, generating new microorganisms that do not cause infection ”, explains the BBVA OpenMind site.

However, these results do not refer to it being the cure against COVID-19, since the purpose was to verify the safety and tolerance of the patients.

There is still a long way to go to make this vaccine available to everyone,

said the researcher in charge of the project, Wei Chen.

In addition, since April, the second phase of trials that included 500 patients, some over 60 years of age, was launched in order to improve the dose of people with the disease.

Vaccine will be a public good: Xi Jinping

On May 18, Chinese President Xi Jinping promised to make vaccine a “global public good” in case the Asian country develops it.

The president said he supported a “comprehensive” and “impartial” assessment of the global response to the coronavirus once the epidemic has been brought under control.

As of May 22, five million 169,907 people had been infected with COVID-19, which had caused the death of 335,993, according to Johns Hopkins University.